Thanks, everyone. Sean, thank you very much for being here. Here we have Olema Oncology CEO, Sean. You guys have had a lot going on, and I feel like we're finally getting to the point where we can actually talk about your data and not someone else's data. Must feel pretty good.
Yeah. We're very confident in the data we've generated to date, and it's a classic question that we have in oncology, which is, are you able to replicate that phase II data in the phase III setting? And obviously in Q1 for OPERA-01, the second line, second, third line study, we will have that readout. OPERA-02, which is the first line study with KISQALI, is enrolling extremely robustly.
Yeah. Can we maybe talk to that before we get into the OPERA-01 stuff?
Yeah.
PERSEVERA didn't work out. SERENA-4 didn't work out. The fact that, I think in the press release on Monday or earlier this week, I can't remember which day it was, but you guys actually said that enrollment is accelerating. Can you speak to why, especially in the wake of some pharma setbacks?
Yeah. Why is that? One thing that you There are a couple reasons for it.
It is absolutely true that persevERA was a negative trial.
Right? It did not meet its hazard ratio. It didn't get its p-value. It is also absolutely true that there's evidence of activity in that trial, right? There are negative trials where you go, "Wow, this really doesn't do anything. And to be perfectly honest, if that had been the result in persevERA, I think we would have some soul searching to do.
Yeah. I mean, five months kind of was the bar going into it.
Five months is absolutely practice changing.
The challenge is that their hazard ratio missed by a few hundredths, actually. There is clear evidence of activity. Now, there is a design flaw in that trial, and the design flaw is including endocrine-resistant patients. If you look at their tables, that is the TFI treatment-free interval, less than 12 months. Those really aren't first-line patients. Those are endocrine-resistant patients, and they're treated actually as second-line patients in the practice guidelines. Where those patients come from is they received an adjuvant therapy, they stopped that adjuvant therapy, they then went on to develop metastatic disease, but that metastatic disease occurred within the first year of their completion. Those patients generally, as I said, are second line. We don't have those patients in OPERA-02. We never did from the beginning, actually almost no one, because of the treatment guidelines.
Yeah.
One thing I think that you have to realize is that, first of all, our phase II data, one year in patients post-CDK4/6 progression, mostly wild type, 30% two prior CDK4/6s. So our phase II data is compelling. The tolerability from that looks like KISQALI plus AI, so there is not a signal there that has people concerned about giving that combination. Then very simply, the control arm is the global standard of care. Right? If you go onto this trial, you get randomized between KISQALI plus letrozole, which is the global standard of care, versus KISQALI plus palbociclib, and the investigators are very interested in the data we've seen in the signal, though not positive that persevERA showed.
Yeah.
I think that's why you get that level of enthusiasm.
Is this fast enrollment than maybe I expected, but maybe not what you expected? Could this maybe lead to the study getting to a point to read out a little bit earlier?
It could, with some caveats. Caveat one is, we may change the study.
Yeah.
The way we would change the study would be to increase the number of patients enrolled.
Okay, why would we do that, and what are we waiting for? We would do that because the assumptions we use for the performance of the control arm are fairly old. They are really the registrational trials for KISQALI and the other CDK4/6 inhibitors. The median PFS in that was a little over two years, 24, 26 months. It is very common in oncology, as you well know, that a drug or regimen performs better over time. Oncologists are very, very good at learning how to manage toxicity, maintain dose intensity, decrease discontinuations, and when you give the medicine better, it works better.
Yeah.
We are looking for more contemporaneous data sets. One is persevERA, which was about 29 months, so we saw a little bit of a signal there.
SERENA-4, the patients are very similar to OPERA-02.
We think that control arm, again, IBRANCE plus AI, is a good indicator. We are going to wait for that data, which is at San Antonio. It is at the beginning of December, and then we will reevaluate. Obviously, if we enroll some more patients, that takes-
Yeah
a little longer. Not a lot longer, because we're enrolling fast.
But then the readout is really dependent on event rate.
Yeah. Makes sense.
Yep.
I know OPERA-01 is really what investors are most focused on right now.
Yes.
Yeah. Have to get through that first.
Yep.
Seems like with OPERA-02, you guys are positioning yourself very well to pull it off, if it could be pulled off, based on design of the trial. A lot of the conversations I have been having with investors on OPERA-01 is very similar. You guys have strategically designed this study to probably most properly do this experiment of if an oral SERD can win in the wild-type, ESR1 wild-type setting. Can you maybe take a second to walk us through how you guys.
What we did?
approach that? Yeah.
Yeah, what we're doing. So, obviously, the basis for this is the design of the drug. This is a monotherapy trial, so one of our key attributes, obviously, is our combinability. Obviously, in OPERA-02, we think that's a massive thing.
Yeah
We present. We've got two more combos now, everolimus and atirmociclib. We'll present at San Antonio, but we've done palbo, ribo, alpelisib, KAT6. We'll get to that.
We'll get into all those combos.
We'll get there. We're doing all of these combinations, and we find that we are able to maintain exposure and not enhance toxicity, which is unique. That doesn't really apply to OPERA-01, right?
Yeah.
Because it's a monotherapy trial. We think that our higher exposure, and we've now updated this with hundreds of patients and data, our half-life is 14 days. We have a much higher exposure than anybody else. Then we're a complete estrogen receptor antagonist. It is our thesis that we're completely locking down the receptor more effectively than others are. The phase II data, 7.3 months median PFS in mutant, 5.5 in wild-type, looks differentiated. It's the classic question, does the phase II replicate in phase III? That's what we're going to find out.
Yep.
But with regard to the trial design, there was one other thing that others have not done that we thought was really important, which is we truly are treating two different populations here, post-progression on CDK4/6 plus AI. ESR1 mutant, where obviously others have had some modest success, about two-month prolongation of PFS, and ESR1 wild-type, where there has been no success.
Yeah.
Right? There is some confusion there. Some people think, investors think, "Oh, in the ESR1 wild-type, the estrogen receptor isn't doing anything anymore." Very clearly not the case, because when you give a targeted therapy, you always have to give an endocrine therapy with it. The question isn't, is the estrogen receptor not doing anything? It is doing something. Is it doing enough that if you inhibit it, you'll get the benefit?
Yeah.
That's what we're trying to answer. The way we answer it is through statistical design. When you go into the trial as a patient investigator, it just looks like one trial. You take the patients who have progressed on CDK4/6, you randomize them, they get fulvestrant or exemestane, it'll be mostly fulvestrant, or palazestrant. You treat them and you follow for PFS. When you get to the analysis, it almost looks like two trials.
Yeah.
Because we analyze the mutant and the wild-type population separately, so that the trial actually, interestingly, has a variety of positive outcomes. You could, what we hope, you could hit mutant and wild-type.
Yeah.
That's not confusing. You could hit mutant only, not hit wild-type. That's a positive trial. Not biologically, but statistically. Biologically, this makes no sense, what I'm about to say. You could hit wild-type only, not hit mutant, and that would be a positive.
Wouldn't that be something?
I would have no idea what that meant, and that would be a nice result.
An upgrade?
but it doesn't make any biological sense.
Yeah.
But it is the statistical.
And these two endpoints, do you think they would not influence whether you got an approval in ESR1? So if you hit in one but not the other, the other endpoint is still safe from a regulatory perspective?
Well, that is what has happened with the others, right? Always in mutant.
Yeah
In that case, of course, and biologically, that makes more sense. But no, that is it. The thing that we are doing, though, is what is really different is we are really giving that chance to test in the wild-type.
Yeah. As far as enrollment.
Yeah
No prior chemo.
Right
at least six months
In the advanced setting, yeah
at least six months of response to their prior line of endocrine therapy, correct?
Yeah.
How do you think that would maybe set you up for the best possibility chance of success here?
Right. What has been used by some others, it was not used in EMERALD, the Radius Menarini trial, but some others have used those criteria. You are trying to select against those truly endocrine-resistant patients. We know from a variety of datasets, but probably most best the EMERALD retrospective, patients who an oncologist decided they need chemotherapy at some point for their metastatic disease, they really just do not do well.
Yeah
No matter what treatment they get. That is one selection. The six months is a little bit of a compromise between you are rolling quickly enough and trying to select out patients who are just, again, truly endocrine-resistant.
Yeah.
And are unlikely to benefit from endocrine monotherapy. We don't think they're great selection, but we hope it does give us some.
Yeah.
What you're really trying to do is you're trying to It's partly the outcome of the trial, but it's partly trying not to enroll patients who you really don't think are going to benefit from these therapies.
Yeah. So, as far as outcomes, investors seem to feel pretty confident you're going to hit an ESR1 mutant.
Yeah.
Then it really just comes down to, is the safety meaningfully better than elacestrant, competition in the commercial setting? But investors seem to think that the ESR1 wild-type is a bit of a coin flip. Do you agree with that sentiment, or do you think it's designed to maybe be a little bit more than a coin flip probability of success-wise?
So first of all, with regard to the mutant- This is oncology. Efficacy drives. Others have definitely seen a benefit, and this is progress for patients, but it's two months. It's two months prolongation.
Yeah.
Sometimes, imlunestrant's 1.7.
There is an opportunity to differentiate there based on efficacy.
Yeah.
If you can, 7.3, will we duplicate that? That looks really good.
Yeah.
You don't quite have to get that far, but you could differentiate on efficacy. I think there's an opportunity to differentiate in the mutant. Going to the wild type, I think first of all, investors are absolutely right. The probability of success has to be higher in the mutant than the wild type.
Yeah.
If you just look at our phase II data, it was 7.3 versus 5.5. That is two months difference.
Right? If you just look at that, you would say that your probability is higher.
Yeah.
You then go back to precedent. Remember, many of the drugs that have succeeded in the mutant are not complete antagonists, so there is a mechanistic difference, and even imlunestrant, which is one, is limited in its exposure. So there are molecular and pharmacological differences there. But the fact that they were able to succeed in mutant even with that, I think.
Yeah
Makes mutants higher PTS.
Makes sense.
We have. Look, we are doing the experiment the way we are because we have some confidence based on our phase II data that there is an opportunity in the wild type.
Yeah.
We will have to see.
Does this mean an oral option could be available to any patient ER-positive breast, post-frontline therapy?
It does.
Would you immediately start thinking about your KAT6 inhibitor? Maybe we shouldn't be doing this fulvestrant combo. Maybe we go all in on palazestrant.
We're thinking about that now. We're thinking about that now. Let me back up.
But just as a combination backbone, like the implications of hitting in both endpoints.
Yes. So the first implication in hitting in both endpoints is that you now have an oral endocrine option for both patients.
There's obviously a market revenue implication, which is you go from a $2 billion, approximately, annual market, which is ESR1 mutant, with competition in it. Opportunity to differentiate, but there's competition there, to a $5 billion market, $3 billion of which doesn't have any competition. Right? That's a massive difference. The $2 billion for where we are, our company size and stuff, is still.
Yeah
A great opportunity. But you go to five and no competition in part of it, that's a big deal. With regard to KAT6 and palazestrant, we're testing it now.
The preclinical data suggests that the thing you want to combine with for inhibition of KAT6 is palazestrant.
Not fulvestrant.
I mean, oral is a clear deal.
Oral's better.
Yeah.
Oral's better, and that's driven by efficacy. It's oncology. That is a real differentiator.
Yeah
As well. The testing is ongoing. At San Antonio, you will not see any of the data.
The reason is that palazestrant OP-3136 is a novel combo.
It moves a little more slowly.
Makes sense.
Than fulvestrant.
OP-3136, where you will see the early data.
Yeah.
Pala combo, I would like mid-year next year, maybe.
Okay
We will be able to share that. The new NUBEQA, the prostate cancer, that enrollment is starting in the near future. That, the soonest, maybe end of year next year. That is on a different timeline.
How fast are you guys ready to file on the back of OPERA-01? Are you already working towards commercial readiness? Assuming that at least one of these endpoints is going to hit.
Right. Yeah. Yes, we are working on both.
I should say, in terms of filing, we are working on being able to file U.S. and ex-U.S.
In terms of commercialization, we are U.S.-focused.
Okay.
We will seek a collaborator.
To we want to be able to file because we don't want to lose time, but we'll seek a collaborator to launch and promote.
Okay
ex-U.S. So we have a commercial, a small but mighty commercial team preparing for launch. We assume that we're going to be able to launch in 2028, maybe mid-year.
Yeah.
It does depend upon the readout
as you said, of course, of OPERA-01. Those launch preparations are underway. Obviously, the OPERA-01 readout, what is the readout
exactly accelerates and potentially changes the scope of those efforts.
Yeah.
But again, that's not that far off.
Yeah. No, time's flying. I can't believe we're almost at San Antonio Breast, which brings me to my transition and
Oh, yeah.
the nearest term catalyst that you guys have. Can you run us through the three posters that you are going to have there and maybe set expectations for how much data to expect?
safety, PK? Will there be efficacy across these?
Yeah. Let us do the palazestrant combos first. Again, as I mentioned, one of the attributes of palazestrant that we really designed in from the beginning, but have very actively tested, is combinability. Just reminding everyone that until you decide to give chemotherapy, you always give an endocrine agent.
Yeah.
All of the targeted agents, PI3 kinases, AKT, mTOR, KAT6,
when it gets there, these things are always combined with an
Yeah
endocrine agent. We've always viewed that combinability as a key property, because we figure you want to give the best targeted agent for the line of therapy or maybe the patient's genetics. Tumor genetics. But you always want to give it with the best endocrine therapy. We also note that others have had trouble. They just don't combine well. Sometimes that's PK interactions, old school pharmacology. Sometimes it's toxicity enhancement.
Yeah.
We haven't seen those things. Now, two of the posters are expanding on that. We have an everolimus data set. The everolimus data set is pretty mature.
Mm-hmm. Okay.
You are going to get Kaplan-Meier, PFS.
Obviously the tolerability.
I think people will, I think, find that interesting.
I think so. Yeah.
We break up by mutant and wild type. That will be interesting for people.
Mm-hmm. Okay.
That, again, is a post-CDK4/6 setting.
Yeah.
The atirmociclib, reminding everyone, atirmociclib is the CDK4 selective molecule being developed by Pfizer. What they are testing in phase III is, by being more selective for inhibiting CDK4 over CDK6, it is very clear that they dial down neutropenia.
Yeah.
The question is, do you enhance efficacy by hitting CDK4 harder? That is being tested. For us, we are looking at that is this the life cycle of palazestrant? You will see the initial combination data with the atirmociclib. Enrollment is completed on that. Tolerability, you will see sort of initial efficacy, kind of response rate stuff.
Okay.
That's a mixture of post-CDK4/6 and frontline patients. These patients, some of them are going to be on for a long time.
Okay.
So that level of maturity won't be there. Everolimus is more mature.
So think of it more as a first look at ORR, but not necessarily durability yet?
No, I don't think you'll see durability. I think, again, you're in a mixed patient population. It's really, the main purpose is to show that once again, here we are combinable.
Mm-hmm. Okay.
Then we share what we have
Yeah
for efficacy.
Makes sense.
That is the way we do it. The KAT6 combination will update our monotherapy. That, again, is primarily breast. We will show our first fulvestrant combo data set. This, again, is from phase I-B. It is at multiple dose levels.
Yeah
Of KAT6. Fulvestrant is always given full dose. So again, you will get combinability from the tolerability standpoint. An expansion of the tolerability data set.
Will this just be the breast patients? I know at ASCO you showed a mix.
The fulvestrant combo is only breast.
Right.
Obviously, yeah.
Yes.
Yeah.
Right. The prostate, that NUBEQA is starting.
Yeah.
That may be end of year next year.
Okay. But as far as the mono safety?
The mono safety, we just use everybody.
Basket. Okay.
We've got.
Yeah.
Yeah, which is interesting because we kind of got a hint that the tolerability might be a little different in breast versus prostate.
Yeah, I remember you guys saying that at ASCO.
Yeah.
That is why I was asking.
Because the prostate patients are older. Some of them have had therapies like prior PLUVICTO.
Which is not a bone marrow friendly.
Yeah
Therapy, even though we saw activity there. You will get some initial kind of response rate data. Remember, multiple dose levels. I think what are investors going to do? They are going to compare with Pfizer. Remember, this is not a phase II. This is multiple dose levels. The other thing I would say is these are more heavily pre-treated patients. I think that. But we are pretty comfortable with it.
Okay.
Palazestrant is enrolling. Mid-year next year, we think we will have data. But that is a really interesting thing because maybe the phase III here is not fulvestrant. Maybe it is palazestrant.
Yeah. I think hitting across all in OPERA-01
Yeah
It would be silly not to take that path.
Well, yeah, that's a no-brainer. That makes it really easy. We'll see.
Yeah.
We'll see how that goes. But even if you don't, it does change the regulatory pathway. But even if you don't get that in OPERA-01, depending upon the data you see with the combo with KAT6
You could still pursue well.
Yes, absolutely.
Okay. I've been getting questions from investors since the San Antonio Breast titles went out.
On what the bar is for the fulvestrant plus KAT6 inhibitor. We've seen Pfizer's combination show roughly around, I think it was around 37%. You're also saying now that was in, you're treating more heavily pre-treated patients.
Yeah.
How should we think about that. Or maybe what would your bar be for internal conviction.
Well, first of all, you have to think about their earlier data. It is interesting with KAT6. The responses do not always come so early. Which is kind of interesting. Remember that their ASCO presentation was 30%. Their publication then was 37.
Yeah.
All that had changed was time.
Yeah. It's not the only epigenetic mechanism where we see that.
They all do that.
Yeah.
They all do that, which is kind of funky.
But you do have to-
But also kind of good, because if it takes time to get to that-
No, no. If you're able to stay on for that long-
Yeah
it's fine.
Yeah.
We really look at more as the 30%.
Okay.
Recognizing, again, that pretty much that patient population was one prior line of therapy.
They were post-CDK4/6
Yeah
plus AI and progressions. But in a phase I-B data set, you get patients who've been.
Yeah
through more therapeutic options. We know for a fact that responsiveness goes down.
Okay
with more prior therapies. I think that's one thing to look at. The other thing is, obviously, we're multiple dose levels. We haven't selected a dose yet for OP-3136. We started at two. We are at 80. It may very well be, we will see, but it may very well
Where did you start the fulvestrant combination?
You will see.
Okay.
You'll see where we started and what we have so far. The palazestrant's a little more complicated because you had to dose escalate both because it's a novel combination.
Yeah
It's enrolling. It's doing great.
Okay.
It's a little bit behind the fulvestrant combination. I do think there will be an opportunity as we get there, when we select a dose or a couple of doses to compare, then obviously the expansion.
Okay
Portion will commence. Our objective here, the reason that we got into combos so quickly is, we see multiple flaws with Project Optimus. But one of the major flaws is it is designed to choose dose based on monotherapy. Why would you do that for a drug you never ever intend to give as a monotherapy?
That's fair.
You really want to be testing a regimen you would test-
in a clinical setting. What we're trying to do is accelerate into that.
Okay. I'm assuming that we should see enough safety to maybe increase conviction that maybe you can combine with a CDK4/6?
Yeah. I mean, I think-
But it's complicated?
You'll see what safety we have.
I think that the safety for really making that determination, and it's in the trial, as you know, that arm is in there. That data really has to come from when you've selected a dose.
Okay
of OP-3136.
Right? It's a question of when you've selected a dose, what is the tolerability at that dose? And in particular, because the dysgeusia, while a real thing, a class effect, epigenetically, more broadly actually, that isn't the thing that's going to determine if you can.
Okay
combine with CDK4/6. What will determine is the bone marrow effect.
Okay. As far as the fulvestrant combo, how close are you to kind of settling on a dose?
We got a ways to go. I mean, we just
Yeah
got a ways to go. I mean, our exposure is very high. We very clearly have
our well in active range. You will see that in the poster. We just need to collect more data.
Yeah
You only get to do this once.
Mm-hmm. You want to do it right.
It is very important to do it well.
Yep. The KAT6 space, some investors highlight, has gotten pretty crowded. We are also seeing some KAT6/7s. Pfizer is obviously in the lead with their KAT6 in the clinic first, in phase III.
For sure.
Where do you guys believe you stand from a competitive positioning perspective?
Right. The KAT6/7 thing is an interesting thing. We are a KAT6/7. So is Pfizer, by the way. Pfizer is probably a KAT5, 6A, 6B, seven, eight. We're kind of more of a 6A, 6B, seven.
Yeah.
We hear a lot, everybody's got one now.
We actually have data.
Yeah
First of all. Beyond that, we have this opportunity to combine with palazestrant.
We'll see how that plays out, obviously, but the preclinical data suggests that's a real advantage. We are the only ones that can do it. The other thing that was really interesting, we really debated putting the prostate cancer patients on the trial or not. The preclinical data was compelling. Our Chief Scientific Officer was like, "We got to do this. One chance, we do it.
We have monotherapy activity. That led to the NUBEQA collaboration with Bayer. I think we have multiple ways to differentiate. Our tolerability did look better. That needs to be expanded. You need to do it at the dose.
Yeah.
Remember, Pfizer at their five milligram dose has 55% discontinuations or dose reductions, mostly due to cytopenias. I think there's a real opportunity there. We have lots of ways to potentially differentiate here.
Seems like internal conviction for KAT6 is pretty high.
It is really high. External conviction is really high. Our enrollment is crazy.
Yeah.
We have waiting lists because we are doing this dose escalation still. So when you open it up, it is just going to dose.
Any type of timeline you can provide for when you might be ready to move the KAT6 into a registrational trial?
We got to get a dose.
Or are we too early?
We got to get a dose. As soon as we get a dose-
I'll keep asking you that every quarter.
I think we can get pretty quick. You can ask. That's a fair question.
As far as what cash runway supports right now?
Yeah. We just, earlier this week, did our Q3, had $414 million cash at the end. That gets us sort of into the launch window for palazestrant, but OPERA-01 has to be positive, of course, fileable in order to do that. Of course, you don't want to go into launch running on fumes.
Yeah.
Access to capital is important. But again, the equity isn't the only way to do that, particularly depending on the OPERA-01 outcome.
Yep.
Right. And the need, as I said, to seek a collaborator to get to rest of world. So, yeah, we're in a favorable cash position for what we need. Data from OPERA-01, but also I think lots of data from KAT6 as well.
Sounds great. Well, a lot coming up around the corner.
Lots going on.
I'm sure there'll be a lot more to chat about in just a couple weeks.
There definitely will be.
Thanks for being here. Thanks everyone for listening. Hope you have a great rest of your conference.
Yeah. Thank you, Laura. Appreciate it.
Of course.